Omeros (NASDAQ:OMER) Lowered to Sell Rating by StockNews.com

Omeros (NASDAQ:OMER) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Omeros Stock Performance

Shares of OMER traded down $0.03 during mid-day trading on Tuesday, reaching $4.26. 303,011 shares of the company’s stock traded hands, compared to its average volume of 396,343. Omeros has a 12 month low of $1.17 and a 12 month high of $5.68. The stock has a market capitalization of $246.85 million, a P/E ratio of -1.81 and a beta of 1.47. The business’s 50-day moving average price is $4.01 and its 200-day moving average price is $4.04.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently modified their holdings of OMER. Vanguard Group Inc. lifted its position in shares of Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after purchasing an additional 81,348 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after purchasing an additional 18,454 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Omeros in the first quarter valued at $538,000. Finally, Rhumbline Advisers lifted its stake in shares of Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 6,435 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.